This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: University Health Network. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Amanda Mitchell: Innovator in Acute Myeloid Leukemia Prognosis
Introduction
Amanda Mitchell is a prominent inventor based in Toronto, Canada. She has made significant contributions to the field of medical research, particularly in the area of acute myeloid leukemia (AML). Her innovative approach to classifying high-risk AML patients has the potential to improve patient outcomes and guide treatment decisions.
Latest Patents
Amanda holds a patent for a method of identifying high-risk AML patients. This patent describes a method for prognosing or classifying a subject with AML by determining the expression level of at least three genes in a test sample. The genes involved include DNMT3B, ZBTB46, NYNRIN, and several others. By comparing the expression levels of these genes in the test sample with reference levels from control samples, the method can classify patients into low-risk or high-risk groups for worse survival.
Career Highlights
Amanda Mitchell is affiliated with the University Health Network, where she conducts her research. Her work is instrumental in advancing the understanding of AML and developing new prognostic tools. With her innovative methods, she aims to enhance the precision of AML treatment and improve patient care.
Collaborations
Amanda collaborates with esteemed colleagues such as Jean Wang and Mark Minden. Their combined expertise contributes to the advancement of research in the field of leukemia and cancer treatment.
Conclusion
Amanda Mitchell is a trailblazer in the field of acute myeloid leukemia research. Her patented method for identifying high-risk patients represents a significant advancement in medical innovation. Through her work, she continues to make a lasting impact on patient care and treatment strategies.